4wzv
From Proteopedia
(Difference between revisions)
Line 5: | Line 5: | ||
</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=AZI:AZIDE+ION'>AZI</scene>, <scene name='pdbligand=CA:CALCIUM+ION'>CA</scene>, <scene name='pdbligand=E40:(2R)-4-(1,3-DIOXO-1,3-DIHYDRO-2H-ISOINDOL-2-YL)-N-HYDROXY-2-{[(4-METHOXYBIPHENYL-4-YL)SULFONYL](PROPAN-2-YLOXY)AMINO}BUTANAMIDE'>E40</scene>, <scene name='pdbligand=EDO:1,2-ETHANEDIOL'>EDO</scene>, <scene name='pdbligand=GOL:GLYCEROL'>GOL</scene>, <scene name='pdbligand=NA:SODIUM+ION'>NA</scene>, <scene name='pdbligand=PEG:DI(HYDROXYETHYL)ETHER'>PEG</scene>, <scene name='pdbligand=PGO:S-1,2-PROPANEDIOL'>PGO</scene>, <scene name='pdbligand=ZN:ZINC+ION'>ZN</scene></td></tr> | </td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=AZI:AZIDE+ION'>AZI</scene>, <scene name='pdbligand=CA:CALCIUM+ION'>CA</scene>, <scene name='pdbligand=E40:(2R)-4-(1,3-DIOXO-1,3-DIHYDRO-2H-ISOINDOL-2-YL)-N-HYDROXY-2-{[(4-METHOXYBIPHENYL-4-YL)SULFONYL](PROPAN-2-YLOXY)AMINO}BUTANAMIDE'>E40</scene>, <scene name='pdbligand=EDO:1,2-ETHANEDIOL'>EDO</scene>, <scene name='pdbligand=GOL:GLYCEROL'>GOL</scene>, <scene name='pdbligand=NA:SODIUM+ION'>NA</scene>, <scene name='pdbligand=PEG:DI(HYDROXYETHYL)ETHER'>PEG</scene>, <scene name='pdbligand=PGO:S-1,2-PROPANEDIOL'>PGO</scene>, <scene name='pdbligand=ZN:ZINC+ION'>ZN</scene></td></tr> | ||
<tr id='related'><td class="sblockLbl"><b>[[Related_structure|Related:]]</b></td><td class="sblockDat">[[4h3x|4h3x]], [[4hma|4hma]], [[4h82|4h82]], [[4h1q|4h1q]], [[4h2e|4h2e]]</td></tr> | <tr id='related'><td class="sblockLbl"><b>[[Related_structure|Related:]]</b></td><td class="sblockDat">[[4h3x|4h3x]], [[4hma|4hma]], [[4h82|4h82]], [[4h1q|4h1q]], [[4h2e|4h2e]]</td></tr> | ||
- | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4wzv FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4wzv OCA], [http://www.rcsb.org/pdb/explore.do?structureId=4wzv RCSB], [http://www.ebi.ac.uk/pdbsum/4wzv PDBsum]</span></td></tr> | + | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4wzv FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4wzv OCA], [http://pdbe.org/4wzv PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=4wzv RCSB], [http://www.ebi.ac.uk/pdbsum/4wzv PDBsum]</span></td></tr> |
</table> | </table> | ||
== Disease == | == Disease == | ||
Line 19: | Line 19: | ||
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> | From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> | ||
</div> | </div> | ||
+ | <div class="pdbe-citations 4wzv" style="background-color:#fffaf0;"></div> | ||
== References == | == References == | ||
<references/> | <references/> |
Revision as of 07:46, 7 October 2015
Crystal structure of a hydroxamate based inhibitor EN140 in complex with the MMP-9 catalytic domain
|